Literature DB >> 20145264

CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.

Mercedes Borge1, Paula Romina Nannini, Jeremías Gastón Galletti, Pablo Elías Morande, Julio Sánchez Avalos, Raimundo Fernando Bezares, Mirta Giordano, Romina Gamberale.   

Abstract

BACKGROUND: T cells from patients with chronic lymphocytic leukemia may play an important role in contributing to the onset, sustenance, and exacerbation of the disease by providing survival and proliferative signals to the leukemic clone within lymph nodes and bone marrow. DESIGN AND METHODS: By performing chemotaxis assays towards CXCL12, CCL21 and CCL19, we sought to evaluate the migratory potential of T cells from chronic lymphocytic leukemia patients. We next analyzed the chemokine-induced migration of T cells, dividing the chronic lymphocytic leukemia samples according to their expression of the poor prognostic factors CD38 and ZAP-70 in leukemic cells determined by flow cytometry.
RESULTS: We found that T cells from patients with chronic lymphocytic leukemia are less responsive to CXCL12, CCL21 and CCL19 than T cells from healthy adults despite similar CXCR4 and CCR7 expression. Following separation of the patients into two groups according to ZAP-70 expression, we found that T cells from ZAP-70-negative samples showed significantly less migration towards CXCL12 compared to T cells from ZAP-70-positive samples and that this was not due to defective CXCR4 down-regulation, F-actin polymerization or to a lesser expression of ZAP-70, CD3, CD45, CD38 or CXCR7 on these cells. Interestingly, we found that leukemic cells from ZAP-70-negative samples seem to be responsible for the defective CXCR4 migratory response observed in their T cells.
CONCLUSIONS: Impaired migration towards CXCL12 may reduce the access of T cells from ZAP-70-negative patients to lymphoid organs, creating a less favorable microenvironment for leukemic cell survival and proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145264      PMCID: PMC2864383          DOI: 10.3324/haematol.2009.013995

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  44 in total

1.  When and how to treat chronic lymphocytic leukemia.

Authors:  G Dighiero; J L Binet
Journal:  N Engl J Med       Date:  2000-12-14       Impact factor: 91.245

2.  Cutting edge: T cell migration regulated by CXCR4 chemokine receptor signaling to ZAP-70 tyrosine kinase.

Authors:  N C Ottoson; J T Pribila; A S Chan; Y Shimizu
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

3.  T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.

Authors:  Angela M Krackhardt; Sabine Harig; Mathias Witzens; Ryan Broderick; Patrick Barrett; John G Gribben
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

4.  T-cell abnormalities in patients with chronic lymphocytic leukemia.

Authors:  Tait Shanafelt; Neil Kay
Journal:  Leuk Lymphoma       Date:  2006-07

5.  CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.

Authors:  J Dürig; M Naschar; U Schmücker; K Renzing-Köhler; T Hölter; A Hüttmann; U Dührsen
Journal:  Leukemia       Date:  2002-01       Impact factor: 11.528

6.  Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.

Authors:  Paolo Ghia; Giuliana Strola; Luisa Granziero; Massimo Geuna; Giuseppe Guida; Federica Sallusto; Nancy Ruffing; Licia Montagna; Paola Piccoli; Marco Chilosi; Federico Caligaris-Cappio
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

7.  SDF-1 responsiveness does not correlate with CXCR4 expression levels of developing human bone marrow B cells.

Authors:  M Honczarenko; R S Douglas; C Mathias; B Lee; M Z Ratajczak; L E Silberstein
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

8.  Human B cells become highly responsive to macrophage-inflammatory protein-3 alpha/CC chemokine ligand-20 after cellular activation without changes in CCR6 expression or ligand binding.

Authors:  Fang Liao; Aiko-Konno Shirakawa; John F Foley; Ronald L Rabin; Joshua M Farber
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

9.  Signaling through ZAP-70 is required for CXCL12-mediated T-cell transendothelial migration.

Authors:  Michel Ticchioni; Céline Charvet; Nelly Noraz; Laurence Lamy; Marcos Steinberg; Alain Bernard; Marcel Deckert
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

10.  Activation of pertussis toxin-sensitive CXCL12 (SDF-1) receptors mediates transendothelial migration of T lymphocytes across lymph node high endothelial cells.

Authors:  Rhian Phillips; Ann Ager
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

View more
  6 in total

1.  The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.

Authors:  Pablo E Morande; Samanta R Zanetti; Mercedes Borge; Paula Nannini; Carolina Jancic; Raimundo F Bezares; Alicia Bitsmans; Miguel González; Andrea L Rodríguez; Carlos M Galmarini; Romina Gamberale; Mirta Giordano
Journal:  Invest New Drugs       Date:  2011-09-02       Impact factor: 3.850

2.  Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients.

Authors:  Tamara Mateu-Albero; Ana Marcos-Jimenez; Stefanie Wissmann; Javier Loscertales; Fernando Terrón; Jens V Stein; Cecilia Muñoz-Calleja; Carlos Cuesta-Mateos
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

3.  Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

Authors:  Alan G Ramsay; Rachel Evans; Shahryar Kiaii; Lena Svensson; Nancy Hogg; John G Gribben
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

4.  From prostate to bone: key players in prostate cancer bone metastasis.

Authors:  Megan N Thobe; Robert J Clark; Russell O Bainer; Sandip M Prasad; Carrie W Rinker-Schaeffer
Journal:  Cancers (Basel)       Date:  2011       Impact factor: 6.639

Review 5.  Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression.

Authors:  Daniel Prieto; Pablo Oppezzo
Journal:  Molecules       Date:  2017-12-05       Impact factor: 4.411

Review 6.  Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.

Authors:  Carlos Cuesta-Mateos; Jennifer R Brown; Fernando Terrón; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.